צמיחת רווח למניה משנה לשנה בשנים עשר החודשים האחרונים: Compass Therapeutics (CMPX)

Compass Therapeutics focuses on developing antibodies to combat solid tumors, advancing the drug CTX-009 to capture the biliary tract treatment niche. This quarterly earnings per share growth chart confirms this trend, where 6.50 reflects the metric's baseline. Drug delivery requires costly temperature control, and the absence of sales makes the stock price dependent on test results and patents.

Compass Therapeutics is optimizing profitability through laboratory diversification and the stockpiling of biocomponents for antibody logistics. This price action reflects comparable quarterly EPS growth, which measures the percentage change in net income per share relative to the previous period. This indicator reveals the actual speed of business scaling by filtering out short-term volatility. Analysis of this chart allows for the determination of the asset's development phase, which is critical for assessing the fair value of capital.